InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
Jim Segermark, CEO
A Non-Opioid Surgical Analgesic
InSitu Biologics is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
- 22+ US Patents Issued, with matching OUS positions
- Hydrogel technology licensed from Cleveland Clinic Foundation
- Tunable, biocompatible, and pH neutral platform
- High dose drug-load reservoir capacity with a predictable pharmacological effect
- Non-opioid pain relief option
InSitu Biologics is hosting a Regulation A+ offering to a limited number of investors.
Filed additional patent(s)
White Paper published
Completed maximum dosing study with no toxicity
Presented at PODD-Boston
Completed first GLP study
Proved more pain relief compared to Exparel in pre-clinical study
GLP publication accepted
Raised over $400k
Completed Financial Audit
Converted all debt
Filed $10,000,000 RegA+ Offering
Launch RegA+ Offering
Announce GLP Paper by Hutchins & Taylor
Begin Phase 1 program manufacturing
Announce final GLP Study results
SEC valuation incorporating Animal Care Market opportunity
Submit GLP results for Peer-Review
FDA Pre-IND meeting
Expect approval for Phase 1 Clinical Study of AnestaGel
Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.
Bill TaylorChief Scientist
Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.